The clinical relevance of viral blipping during nucleos (t) ide analogue (NA) treatment is unclear in chronic hepatitis B (CHB). We investigated the prevalence, risk factors and clinical outcomes for those with viral blipping during NA treatment. A retrospective cohort study investigated consecutively treated CHB patients from May 2008 to February 2015 on the NAs such as entecavir (ETV), tenofovir (TDF) and lamivudine (LAM). Included patients were previously treatment naive. Viral blipping was defined as serum HBV DNA >20 IU/mL on one occasion, and not >200 IU/mL, with subsequent measurement returning to undetectable levels, that is <20 IU/mL. A total of 242 treatment-compliant CHB patients were included with 44 (18.2%) experiencing viral blipping. In multivariable Cox regression, Asian race (HR=7.40, 95% CI 1.01-54.29, P<.049), LAM therapy (vs ETV/TDF, HR=2.53, 95% CI 1.29-4.95, P<.007), higher creatinine (per SD, HR=1.47, 95% CI 1.21-1.79, P<.001), HBeAg positivity (HR=2.68, 95% CI 1.39-5.03, P<.003) and longer time to achieve undetectable HBV DNA (per month, HR=1.05, 95% CI 1.02-1.08, P=.001) were associated with an increased risk of viral blipping. Viral blipping did not show any significant association with viral breakthrough, HBsAg loss, ALT flares or disease progression. Viral blipping is a frequent event during NA therapy; however, it did not lead to any clinically significant outcomes. Thus, it may not require more frequent blood work and patient visits in clinical practice.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jvh.12579 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Changes to inflammatory markers during 5 years of viral suppression and during viral blips in people with HIV initiating different integrase inhibitor based regimens.
Front Immunol
November 2024
Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, United States.
Background: Heightened levels of inflammatory markers are linked to increased morbidity/mortality in people with HIV (PWH) and often remain elevated after virologic suppression by antiretroviral therapy (ART). As new combinations of ART become available, an evaluation of their effects on immune activation and inflammation is warranted. Additionally, it remains unknown whether transient increases in viral load ("blips") during ART are associated with increases in inflammation.
View Article and Find Full Text PDFUsing machine learning techniques to predict viral suppression among people with HIV.
J Acquir Immune Defic Syndr
November 2024
South Carolina SmartState Center for Healthcare Quality, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA , 29208.
Article Synopsis
- This study explores the effectiveness of machine learning algorithms in predicting viral suppression among people living with HIV in South Carolina.
- The data was collected from adult patients diagnosed between 2005 and 2021, focusing on various predictors like demographics, healthcare use, and previous viral load information.
- Results showed that the Long Short-Term Memory (LSTM) model significantly outperformed traditional statistical methods, indicating its potential for better risk prediction in managing HIV.
Chemsex and rising substance use linked to sexually transmitted infections among men who have sex with men living with HIV in Bangkok, Thailand.
IJID Reg
December 2024
SEARCH Research Foundation, Bangkok, Thailand.
Objectives: We report longitudinal trends in alcohol and recreational drug use, and their associations with sexual behaviors and clinical outcomes in a Thai cohort of predominantly men who have sex with men (MSM) living with HIV.
Methods: From 2017 to 2019, participants in the RV254/SEARCH010 acute HIV cohort answered questions every 24 weeks about drug use and sexual behaviors. Longitudinal trends were assessed using the χ2 test for trend.
High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre-existing HIV resistance and suboptimal adherence.
J Med Virol
October 2024
Gilead Sciences, Inc., Foster City, California, USA.
Article Synopsis
- The BRAAVE study (NCT03631732) was a Phase 3b trial focusing on switching Black individuals with suppressed HIV to a new treatment (B/F/TAF) and showed positive results after 72 weeks.
- Participants included those with various pre-existing drug resistance, yet had high rates of virologic suppression, with 99% achieving undetectable HIV-1 RNA levels.
- Notably, despite some adherence challenges and occasional viral blips, no new drug resistance emerged, indicating B/F/TAF’s effectiveness even with resistant strains of HIV.
Background: This study aimed to investigate factors contributing to non-sustained viral suppression, including intermittent viremia and persistent low-level viremia, during cabotegravir (CAB) plus rilpivirine (RPV) long-acting (LA) injectable therapy, with a focus on pharmacokinetics (PK).
Methods: A prospective cohort study was conducted on people with HIV (PWH) transitioning from stable oral antiretroviral therapy (ART) to bimonthly CAB+RPV LA. Standardized follow-up included close monitoring through blood sampling for plasma HIV-1 viral load (VL) and multiple plasma drug concentrations measurements to analyze the connection between PK parameters and virologic outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!